Chlorophyllin for Health & Longevity - Quick Reference Sheet

Chlorophyllin for Health & Longevity

Created on 10/19/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Chlorophyllin is a water-soluble oral dietary supplement derived from plant chlorophyll used to bind dietary toxins in the gut and control body odor. Administered orally with meals, it reduces absorption of foodborne mold and charred-meat toxins, whereas odor trials are conflicted and lifespan claims lack human evidence. It is well tolerated but tints stool green, triggers false-positive chemical stool blood tests, and rarely causes sun sensitivity. (Full Review)

Protocol

Standard chemopreventive protocol
100 mg three times daily (300 mg/day)
Oral sodium copper chlorophyllin with meals; split mealtime dosing preferred
Best time of day
Immediately before or at start of meals
Administered with meals containing potential dietary mutagens (grilled meats, grains, nuts)
Alternative regimens
100–300 mg/day (odor); 120–750 mg/day (clinical)
180 mg/day for trimethylaminuria; 120 mg/day for leukopenia; 500–750 mg/day for radioprotection
Time to effect
Intraluminal carcinogen binding
First meal
Gut toxin trapping begins immediately; urinary DNA adduct reduction assessed at 4 months
Leukocyte recovery
4 weeks
Peripheral white blood cell recovery assessed in clinical leukopenia
Urinary trimethylamine reduction
1–3 weeks
Free urinary trimethylamine reduction in trimethylaminuria

Benefits

Contraindications
  • Individuals with Wilson disease or biliary copper-excretion disorders (sodium copper chlorophyllin formulations)
  • Individuals with cutaneous porphyrias, pseudoporphyria, or severe photosensitivity disorders
  • Pregnant and lactating women
  • Children under 12 years of age without physician supervision
Key Interactions
  • Photosensitizing prescription drugs (doxycycline, voriconazole): Caution (theoretical)
  • Planar aromatic drugs and CYP substrates (doxorubicin, warfarin): Caution (theoretical)
  • Over-the-counter oral drugs and laxatives (ibuprofen, loperamide): Caution (theoretical)
  • Copper, zinc, and polyphenol supplements (copper gluconate, green tea catechins): Monitor (theoretical)
  • Photosensitizing herbal supplements (St. John's wort, dong quai): Caution (theoretical)
  • Diagnostic stool tests and phototherapy (gFOBT, ultraviolet-A phototherapy): Caution

Risk & Side Effects

  • High:
  • Medium:
  • Low: Mild gastrointestinal distress; harmless green discoloration of stool, urine, saliva, and serum; false-positive guaiac fecal occult blood tests; cutaneous photosensitivity and pseudoporphyria; local irritation and hypersensitivity from topical formulations
  • Speculative: Context-dependent colon tumor promotion; systemic copper accumulation

Monitoring

Marker Target Why
Serum copper and ceruloplasmin Copper: 70–140 μg/dL; Ceruloplasmin: 20–40 mg/dL Safety check: detects systemic copper accumulation that stops or changes use
Hepatic panel (ALT, AST, total bilirubin) ALT: 7–56 U/L; AST: 8–33 U/L; Bilirubin: 0.1–1.2 mg/dL Safety check: detects cholestasis or liver injury that stops use
Complete blood count (CBC) with differential White blood cells: 4.5–11.0 × 10³/μL; Hemoglobin: 13.5–17.5 g/dL in men, 12.0–15.5 g/dL in women Expected to change: tracks leukocyte recovery or anemia response with iron-chelated forms
Urinary TMAO-to-total-TMA ratio >90% TMAO / (TMA + TMAO) Expected to change: confirms reduction of free urinary TMA in trimethylaminuria

Cadence: Baseline; 4 weeks for targeted hematologic or odor-control regimens; 12 weeks for initial systemic safety verification; every 6–12 months during chronic daily supplementation (with a 5–7 day pause before guaiac-based stool occult blood screening).

Qualitative Assessment

  • Digestive comfort: Absence of cramps or watery diarrhea alongside expected green stool.
  • Skin sun tolerance: Absence of hand or facial redness, fragility, or blistering.
  • Perceived odor: Reduced body, urinary, or ostomy odor when targeting deodorization.